6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Originaltext

Diese Übersetzung bewerten

Mit deinem Feedback können wir Google Übersetzer weiter verbessern

Latest Press Releases

Time	Headline
7m ago	ProWood TrueFrame Joist Now Available Across Northeast, South Atlantic
7m ago	Parker to Acquire CIRCOR’s Commercial and Defense Aerospace Business
7m ago	Toll Brothers Announces Cedar Terrace Community Now Open in Chantilly, Virginia
8m ago	When Blood Compatibility Becomes a Pregnancy Risk
8m ago	Tony and Grammy Award-Winning Leslie Odom, Jr. to Headline Blackbaud's bbcon 2026 Social Impact Tech Conference

About

53.07USD+2.86 +5.71%

Closed • Updated at 13:55 GMT+00:00

Market Cap$10.26B

P/E Ratio38.72

Volume329.4K

Beta0.55

RSI49.05

Gross Margin76.28%

Health TechnologyBiotechnology

Biomarin Pharmaceutical Inc. — investor relations, events, news, and company updates on 6ix.

Latest News

BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia

BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency

BioMarin Reports First Quarter 2026 Financial and Operating Results

BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

BioMarin Completes Acquisition of Amicus Therapeutics

Community Chat

Ask AI